Skip to content

US · PVLA · BIOTECHNOLOGY

Palvella Therapeutics, Inc. (PVLA) intrinsic value and stock valuation

$142.85as of 2026-11-21 · Mkt cap 2.26B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Palvella Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values PVLA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PVLA’s statements →

Palvella Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Wayne, PA 19087 palvellatx.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-41.72M
20212025
Free cash flow
-$-25.01M
20202025
Total equity
$28M-2% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$25.9M$31.4M
Operating income-$-38.6M-$-14.1M-$-11.87M-$-43.47M-$-51.83M
Net income-$-41.72M-$-17.43M$18.7M-$-33.28M-$-45.74M
EPSd-$-3.71M-$-7.82M$14.7M-$-35.78M-$-56.47M
Operating cash flow-$-25.01M-$-10.84M-$-13.7M-$-14.84M-$-7.66M
Capital expenditure$0.00$0.00$0.00$0.00-$-950K
Free cash flow-$-25.01M-$-10.84M-$-13.7M-$-14.84M-$-8.61M
Total assets$59.6M$88.2M$7.55M$16.5M$153.6M
Total debt$630K$0.00$0.00$0.00$14.9M
Net debt-$-57.35M-$-83.6M-$-7.35M-$-16.05M-$-102.87M
Total equity$28M$62.6M-$-3.88M-$-23.17M$50.8M
Cash and short-term investments$58M$83.6M$7.35M$16.1M$117.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$25.9M$31.4M
Cost of revenue$0.00$0.00$0.00$2.78M$2.37M
Gross profit$0.00$0.00$0.00$23.1M$29.1M
Research and development expenses$22.8M$8.15M$8.79M$50.2M$64.2M
Selling, general and administrative expenses$15.8M$5.94M$3.08M$16.4M$16.7M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$38.6M$14.1M$11.9M$66.6M$80.9M
Cost and expenses$38.6M$14.1M$11.9M$69.4M$83.3M
Interest income$2.59M$640K$6.26M$720K$0.00
Interest expense$5.82M$4.32M$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$2.78M$2.37M
Ebitda-$-35.9M-$-13.12M$18.7M-$-30.5M-$-43.37M
Operating income-$-38.6M-$-14.1M-$-11.87M-$-43.47M-$-51.83M
Total other income/expenses, net-$-3.11M-$-3.34M$30.6M$10.2M$6.09M
Income before tax-$-41.72M-$-17.43M$18.7M-$-33.28M-$-45.74M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-41.72M-$-17.43M$18.7M-$-33.28M-$-45.74M
Weighted average shares outstanding$11.3M$2.23M$1.27M$930K$810K
Weighted average diluted shares outstanding$11.3M$2.23M$1.27M$930K$810K
Balance sheet
20252024202320222021
Cash and short-term investments$58M$83.6M$7.35M$16.1M$117.8M
Net receivables$0.00$2.34M$0.00$0.00$3.31M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$59M$88.2M$7.55M$16.5M$127.6M
Property, plant and equipment, net$570K$0.00$0.00$0.00$23M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$570K$0.00$0.00$0.00$25.9M
Total assets$59.6M$88.2M$7.55M$16.5M$153.6M
Accounts payable$4.59M$4.59M$940K$3.18M$8.61M
Short-term debt$200K$0.00$0.00$0.00$1.05M
Deferred revenue$0.00$0.00$0.00$0.00$25.1M
Total current liabilities$11.3M$12M$2.36M$5.78M$50.6M
Long-term debt$430K$0.00$0.00$0.00$13.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$38.4M
Total non-current liabilities$20.2M$13.6M$9.07M$33.9M$52.2M
Capital lease obligations$200K$0.00$0.00$0.00$13.8M
Total liabilities$31.6M$25.6M$11.4M$39.7M$102.8M
Common stock$10K$10K$0.00$0.00$70K
Retained earnings-$-135.45M-$-93.73M-$-76.3M-$-94.99M-$-257.14M
Accumulated other comprehensive income (loss)$80K$0.00$0.00$0.00$830K
Total equity$28M$62.6M-$-3.88M-$-23.17M$50.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$630K$0.00$0.00$0.00$14.9M
Net debt-$-57.35M-$-83.6M-$-7.35M-$-16.05M-$-102.87M
Cash flow statement
20252024202320222021
Net income-$-41.72M-$-17.43M$18.7M-$-27.55M-$-45.74M
Depreciation and amortization$0.00$0.00$0.00$0.00$2.37M
Stock-based compensation$6.4M$830K$600K$430K$0.00
Change in working capital$3.82M-$-190K-$-3.15M$1.62M$30.5M
Accounts receivable$2.49M-$-1.98M$0.00$0.00-$-1.81M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.26M$2.24M-$-2.25M$1.98M$7.05M
Net cash provided by operating activities-$-25.01M-$-10.84M-$-13.7M-$-14.84M-$-7.66M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00-$-950K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00-$-950K
Common stock issued$760K$0.00$0.00$0.00$59.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-660K$87.1M$5M$9.57M$59.1M
Net change in cash-$-25.62M$76.3M-$-31.29M-$-5.27M$47.3M
Cash at end of period$58M$83.6M$7.35M$16.1M$117.8M
Operating cash flow-$-25.01M-$-10.84M-$-13.7M-$-14.84M-$-7.66M
Capital expenditure$0.00$0.00$0.00$0.00-$-950K
Free cash flow-$-25.01M-$-10.84M-$-13.7M-$-14.84M-$-8.61M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Palvella Therapeutics, Inc.

        Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

        CEO
        Wesley H. Kaupinen
        Employees
        29
        Beta
        -0.17

        Explore

        Frequently asked questions

        What is the intrinsic value of Palvella Therapeutics, Inc. (PVLA)?

        InvestorsCraft does not currently publish an intrinsic value for PVLA. How the IC value is calculated.

        Is PVLA undervalued?

        InvestorsCraft does not publish an undervaluation signal for PVLA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.